Sumary of Public Health Watch: Risk of CVST Following Receipt of J&J COVID-19 Vaccine Rare:
- Among the few serious adverse events linked with the 3 currently approved COVID-19 vaccines available in the United States, reports of cerebral venous sinus thrombosis (CVST) following receipt of the 1 dose Ad26.COV2.S (Johnson &
- However, new research published on November 1 by JAMA Internal Medicine once again suggests that, as a vaccine-related adverse event, CVST remains extremely rare, with just 39 cases of acute incident CVST among nearly 2.2 million doses administered.
- Notably, 29 of the affected patients (74.4%) had a predisposing venous thromboembolism risk factor, due to an infection, active cancer, or oral contraceptive use, among others, within 92 days of developing CVST.
- They then used data from the US Centers for Disease Control and Prevention’s Vaccine Adverse Event Reporting System (VAERS) for the period from February 28, the date Ad26.COV2.S received its emergency use authorization from the US Food and Drug Administration, through May 7 to estimate the incidence of CVST following receipt of the vaccine.